Curriculum vitae Prof. Dr. Bernhard Hemmer

Training

• 1984 - 1991 Medical School, University of Freiburg
• 1992 MD
• 1991 - 1994 Resident at the Department of Neurology, University of Freiburg
• 1995 - 1998 Research Fellow at the NINDS, National Institutes of Health, Bethesda, USA
• 1998 - 2001 Resident at the Department of Neurology, University of Marburg

Academic positions & appointments

• 2001 - 2003 Assistant Professor at the Department of Neurology, University of Marburg
• 2004 - 2007 Associate Professor and vice chair of the Department of Neurology, University of Düsseldorf
• since 2007 Professor (W3) and Head of the Department of Neurology, TU of Munich
• since 2010 Vice dean of the medical school, TU of Munich

Research coordination

• since 2007 PI of several multiple sclerosis treatment trials (e.g. Alemtuzumab, BG12, Atacicept)
• since 2008 Member of the executive advisory board of the German MS society
• since 2009 Advisory board member of several phase II and III trials (e.g. Interferon-beta1b, Siponimod, Daclizumab, Ocrelizumab)
• since 2009 Scientific board member of the German Multiple Sclerosis competence network co-speaker (2009-2012), speaker (2012-2016), secretary (since 2016))
• since 2012 Scientific Board member, Munich Cluster of Systems Neurology
• since 2012 Member of the executive committee of the European congress for the treatment and research in multiple sclerosis (treasurer (2012-2016), vice-president (since 2016))
• since 2017 Executive Board member, EU Consortium MultipleMS

Membership in Editorial Boards and societies

• since 2009 Advisory Board Member of the Archives of Neurology, Experimental Neurology, Multiple sclerosis Journal

Awards & honors

• 1995 - 1997 Stipend of the Deutsche Forschungsgemeinschaft (Post-doctoral Fellowship)
• 1997 - 1998 Fogarty stipend, National Institutes of Health, USA
• 1998 Langheinrich Award
• 2000 Heisenberg award of the Deutsche Forschungsgemeinschaft
• 2000 Heinrich-Pette award of the German Neurological Society
• 2013 Sobek-Forschungspreis

10 key papers

• Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS. ORATORIO Clinical Investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376:209-20 (2017)
• Herwerth M, Kalluri SR, Srivastava R, Kleele T, Kenet S, Illes Z, Merkler D, Bennett JL, Misgeld T*, Hemmer B*. In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica-related pathology. Ann Neurol epub ahead of print (2016)
  * equal contributing senior authors
• Andlauer TF, Buck D, Antony G, Bayas A, Bechmann L, Berthele A, Chan A, Gasperi C, Gold R, Graetz C, Haas J, Hecker M, Infante-Duarte C, Knop M, Kümpfel T, Limmroth V, Linker RA, Loleit V, Luessi F, Meuth SG, Mühlau M, Nischwitz S, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Arloth J, Weber P, Radivojkov-Blagojevic M, Scheinhardt MO, Dankowski T, Bettecken T, Lichtner P, Czamara D, Carrillo-Roa T, Binder EB, Berger K, Bertram L, Franke A, Gieger C, Herms S, Homuth G, Ising M, Jöckel KH, Kacprowski T, Kloiber S, Laudes M, Lieb W, Lill CM, Lucae S, Meitinger T, Moebus S, Müller-Nurasyid M, Nöthen MM, Petersmann A, Rawal R, Schminke U, Strauch K, Völzke H, Waldenberger M, Wellmann J, Porcu E, Mulas A, Pitzalis M, Sidore C, Zara I, Cucca F, Zoledziewska M, Ziegler A, Hemmer B*, Müller-Myhsok B*. Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. Sci Adv 17:1501678 (2016)
  * These authors contributed equally to this work.
• Srivastava R, Aslam M, Kalluri SR, Schirmer L, Buck D, Tackenberg B, Rothhammer V, Chan A, Gold R, Berthele A, Bennett JL, Korn T, Hemmer B. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 367:115-23 (2012)
• Brilot F, Dale RC, Selter RC, Grummel V, Kalluri SR, Aslam M, Busch V, Zhou D, Cepok S, Hemmer B. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol. 66:833-42 (2009)
• Bennett J, Lam C, Reddy S, Bautista K, Dupree C, Glogowska M., Case D., Antel J, Owens G, Gilden D, Nessler S, Stadelmann C, Hemmer B. Intrathecal pathogenic anti-Aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 66:617-29 (2009)
• Cepok S, Zhou D, Srivastava R, Grummel V, Büssow K, Nessler S, Sommer N, Hemmer B. Identification of Epstein-Barr-Virus proteins as putative targets of the immune response in multiple sclerosis, J Clin Invest 115:1352-60 (2005)
• Cepok S, Rosche B, Grummel V, Vogel F, Zhou D, Sayn J, Sommer N, Hartung HP, Hemmer B. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 128:1667-76 (2005)
• Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 3:291-391 (2002)
• Hemmer B, Gran B, Zhao Y, Marques A, Pinilla C, Pascal J, Tzou A, Kondo T, Cortese I, Bielekova B, Straus S, McFarland HF, Houghten R, Simon R, Martin R. Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease. Nat Med 5:1375-82 (1999)
• Hemmer B, Fleckenstein BT, Vergelli M, Jung G, McFarland HF, Martin R, Wiesmüller KH. Identification of high potency microbial and self-ligands for a human autoreactive class-II restricted T cell clone. J Exp Med 185:1651-60 (1997)